PERTH, Australia & BOSTON--(BUSINESS WIRE)--corporatefile.com.au
pSivida Ltd. (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) announced Monday an amendment to its license and collaboration agreement with Alimera Sciences relating to Medidur™ FA whereby pSivida’s share of future profits will decrease from 50% to 20% percent in return for Alimera’s payment of up to US$78 million. What is the strategic rationale for this transaction?
